Clinical Trials Sponsored by Pari Pharma GmbH

Total 1265 results

UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany
UCB Pharma GmbH

Completed

Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)

Rheumatoid Arthritis

Germany
UCB Pharma GmbH

Completed

Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch (NON-GI)

Idiopathic Parkinson's Disease

Germany
CellAct Pharma GmbH
Mundipharma-EDO GmbH

Terminated

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors (CAP7-1)

Advanced Endstage Solid Carcinomas in Adults

Germany
Ever Neuro Pharma GmbH
acromion GmbH

Completed

Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease (Combi)

Alzheimer Disease

Spain
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Ever Neuro Pharma GmbH
VASCage GmbH

Terminated

IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE (IMPULSE)

Chronic Stroke | Subacute Stroke

Austria
AIO-Studien-gGmbH
Amgen; WiSP Wissenschaftlicher Service Pharma GmbH

Completed

ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction (NEOPECX)

Stomach Neoplasms | Gastroesophageal Junction Neoplasms

Germany
UCB Pharma
SCHWARZ BIOSCIENCES GmbH - Part of UCB Group

Completed

A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy

Germany
UCB Pharma
SCHWARZ BIOSCIENCES GmbH - Part of UCB Group

Completed

A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy

Germany
Sumitomo Pharma Switzerland GmbH

Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Endometriosis | Uterine Fibroids

United States
Sumitomo Pharma Switzerland GmbH

Recruiting

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)

Prostate Cancer

United States
Dr. Falk Pharma GmbH

Recruiting

Norursodeoxycholic Acid vs. Placebo in NASH

Nonalcoholic Steatohepatitis

Austria
Dr. Falk Pharma GmbH

Completed

Different Doses of ZED1227 vs. Placebo in NAFLD (NormaliZED)

NAFLD | Liver Fibrosis

Germany
Dr. Falk Pharma GmbH

Completed

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Eosinophilic Esophagitis

Switzerland
Dr. Falk Pharma GmbH

Completed

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Incomplete Microscopic Colitis

Germany, Sweden
Dr. Falk Pharma GmbH

Terminated

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

France, Germany
Dr. Falk Pharma GmbH

Completed

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Proctitis

Germany
Dr. Falk Pharma GmbH

Completed

Pharmacokinetic Investigation of UDCA in Bile and Serum

Healthy

Netherlands
Ever Neuro Pharma GmbH

Withdrawn

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) (DAT)

Alzheimer Disease

Austria
Dr. Falk Pharma GmbH

Terminated

Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Radiation Proctitis

Germany
Sumitomo Pharma Switzerland GmbH

Not yet recruiting

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk
Dr. Falk Pharma GmbH

Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Primary Sclerosing Cholangitis

Austria, Germany
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (REPLACE-CV)

Prostate Cancer

United States
Mitsubishi Tanabe Pharma GmbH

Completed

Safety of Argatroban Infusion in Conduction Disturbances (SAICoDis)

Stable Coronary Artery Disease (CAD) | Unstable Angina (Troponin Negative)

Germany
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (SERENE)

Contraception

United States, Puerto Rico
Dr. Falk Pharma GmbH

Completed

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis (EOS-2)

Eosinophilic Esophagitis

Germany
Ever Neuro Pharma GmbH

Terminated

The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery (CAPTAIN)

Traumatic Brain Injury

Hong Kong
Dr. Falk Pharma GmbH

Completed

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea (ERASE)

Traveler's Diarrhea

Ecuador, Guatemala, India
Dr. Falk Pharma GmbH

Completed

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Lymphocytic Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide 9 mg Capsules in Active UC (TOPICAL-1)

Colitis, Ulcerative

Germany
Dr. Falk Pharma GmbH

Terminated

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

Diverticulitis

United States
Dr. Falk Pharma GmbH

Completed

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis (EOS-1)

Eosinophilic Esophagitis

Germany
Dr. Falk Pharma GmbH

Completed

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

Active Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study

Colonic Diverticulosis

Germany
Dr. Falk Pharma GmbH

Completed

OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease (TRUST-2)

Crohn´s Disease

Germany
Harras Pharma Curarina GmbH

Completed

Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2)

Diabetes Mellitus, Type 2

Slovakia
Sumitomo Pharma Switzerland GmbH

Recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk

United States
Dr. Falk Pharma GmbH

Recruiting

Different Doses of Naronapride vs. Placebo in Gastroparesis (MOVE-IT)

Gastroparesis

Belgium
Sumitomo Pharma Switzerland GmbH

Recruiting

Congenital Athymia Patient Registry

Complete DiGeorge Anomaly | Complete DiGeorge Syndrome | Congenital Athymia

United States
Croma-Pharma GmbH
Hugel

Completed

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines (H2H)

Frown Lines

United States, Austria, Canada
Dr. Falk Pharma GmbH

Completed

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (PROTECT-2)

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Autoimmune Hepatitis

Germany
Dr. Falk Pharma GmbH

Completed

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Uncomplicated Diverticulitis

Germany
Dr. Falk Pharma GmbH

Terminated

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Diverticulitis

Germany
Dr. Falk Pharma GmbH

Terminated

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (PROTECT-1)

Ulcerative Colitis

Germany

3

Subscribe